查看购物车
  • Traditional Chinese
  • English
封面
市场调查报告书
商品编码
1621721

实体肿瘤检测市场机会、成长动力、产业趋势分析与预测 2024 - 2032

Solid Tumor Testing Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2024 - 2032
出版日期: | 出版商: Global Market Insights Inc. | 英文 105 Pages | 商品交期: 2-3个工作天内

价格
简介目录

2023 年，全球实体瘤检测市场估值为205 亿美元，预计2024 年至2032 年复合年增长率为7.6%。的提高。癌症盛行率的上升极大地推动了对有效诊断能力的需求。随着医疗保健提供者遇到越来越多的患有各种实体瘤的患者，他们有动力增强他们的测试方法，以确保有效治疗和管理疾病。市场可分为基因检测和常规检测。

2023年，基因检测成为主导领域，占136亿美元。此类测试提供了对肿瘤分子和遗传特征的全面了解，有助于制定个人化治疗策略。透过将治疗与特定的基因突变结合起来，基因检测可以改善患者的治疗结果。在考虑应用时，实体肿瘤检测市场涵盖多种类型，包括乳癌、肺癌、摄护腺癌、大肠直肠癌和黑色素瘤等。

专注于乳癌的细分市场占据了最大的市场份额，反映出这种疾病在全球范围内的高发病率，尤其是在女性中。这种盛行率强调了乳癌护理中对早期诊断和有效治疗方案的巨大需求。在北美，实体瘤检测市场2023年收入为77亿美元，预计在预测期内复合年增长率为7.3%。这种增长的一个关键驱动力是对精准肿瘤学的日益关注，它根据个别肿瘤基因谱进行个人化治疗。

市场范围
开始年份 2023年
预测年份 2024-2032
起始值 205 亿美元
预测值 394 亿美元
复合年增长率 7.6%

此外，次世代定序 (NGS) 等基因组技术的进步彻底改变了实体肿瘤检测，可以对癌症突变和分子生物标记进行深入分析。随着市场的不断发展，对早期检测和个人化治疗方法的重视可能会塑造实体肿瘤检测的未来，满足对更有效的癌症管理解决方案不断增长的需求。创新技术的整合将提高诊断准确性，并有助于改善各种癌症类型的患者预后。

目录

第 1 章：方法与范围

第 2 章：执行摘要

第 3 章：产业洞察

  • 产业生态系统分析
  • 产业影响力
    • 成长动力
      • 癌症发生率上升
      • 诊断技术的进步
      • 意识和需求不断增长
      • 增加医疗支出和投资
    • 产业陷阱与挑战
      • 资本要求高
  • 成长潜力分析
  • 监管环境
  • 技术景观
  • 报销场景
  • 未来市场趋势
  • 差距分析
  • 波特的分析
  • PESTEL分析

第 4 章：竞争格局

  • 介绍
  • 公司市占率分析
  • 公司矩阵分析
  • 主要市场参与者的竞争分析
  • 竞争定位矩阵
  • 战略仪表板

第 5 章：市场估计与预测：按类型，2021 - 2032

  • 主要趋势
  • 基因检测
    • 新一代定序（NGS）
    • 萤光原位杂交（FISH）
    • 聚合酶炼式反应 (PCR)
    • 原位杂交（ISH）
  • 常规测试

第 6 章：市场估计与预测：按应用分类，2021 - 2032

  • 主要趋势
  • 乳癌
  • 肺癌
  • 摄护腺癌
  • 大肠直肠癌
  • 黑色素瘤
  • 其他应用

第 7 章：市场估计与预测：按最终用途，2021 - 2032 年

  • 主要趋势
  • 医院
  • 诊断实验室
  • 癌症研究机构
  • 其他最终用途

第 8 章：市场估计与预测：按地区，2021 - 2032

  • 主要趋势
  • 北美洲
    • 我们
    • 加拿大
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 西班牙
    • 义大利
    • 荷兰
    • 欧洲其他地区
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 澳洲
    • 韩国
    • 亚太地区其他地区
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
    • 拉丁美洲其他地区
  • 中东和非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿联酋
    • 中东和非洲其他地区

第 9 章：公司简介

  • Abbott
  • Agilent Technologies, Inc.
  • Caris Life Sciences
  • F. Hoffmann-La Roche Ltd
  • Foundation Medicine, Inc.
  • Guardant Health
  • Hologic, Inc.
  • Illumina, Inc.
  • MedGenome
  • Myriad Genetics, Inc.
  • NeoGenomics Laboratories
  • QIAGEN
  • Quest Diagnostics Incorporated
  • SOPHiA GENETICS
  • Thermo Fisher Scientific, Inc.
简介目录
Product Code: 11699

The Global Solid Tumor Testing Market was valued at USD 20.5 billion in 2023 and is projected to grow at a CAGR of 7.6% from 2024 to 2032. This growth is driven by an increase in cancer cases and heightened awareness regarding the importance of timely and accurate diagnostic solutions. The rising prevalence of cancer significantly fuels the demand for effective diagnostic capabilities. As healthcare providers encounter more patients with various solid tumors, they are motivated to enhance their testing methodologies to ensure effective treatment and management of the disease. The market can be categorized into genetic testing and conventional testing.

In 2023, genetic testing emerged as the dominant segment, accounting for USD 13.6 billion. This type of testing offers comprehensive insights into the molecular and genetic profiles of tumors, which facilitates personalized treatment strategies. By aligning therapies with specific genetic mutations, genetic testing can lead to improved patient outcomes. When considering applications, the solid tumor testing market encompasses various types, including breast cancer, lung cancer, prostate cancer, colorectal cancer, and melanoma, among others.

The segment focused on breast cancer held the largest market share, reflecting the high rates of this disease globally, especially among women. This prevalence underscores the significant need for early diagnosis and effective treatment options in breast cancer care. In North America, the solid tumor testing market generated revenue of USD 7.7 billion in 2023 and is expected to grow at a CAGR of 7.3% during the forecast period. A key driver of this growth is the increasing focus on precision oncology, which personalizes treatment based on individual tumor genetic profiles.

Market Scope
Start Year2023
Forecast Year2024-2032
Start Value$20.5 Billion
Forecast Value$39.4 Billion
CAGR7.6%

Furthermore, advancements in genomic technologies, such as next-generation sequencing (NGS), have revolutionized solid tumor testing, allowing for in-depth analysis of cancer mutations and molecular biomarkers. As the market continues to evolve, the emphasis on early detection and personalized treatment approaches is likely to shape the future of solid tumor testing, addressing the growing demand for more effective cancer management solutions. The integration of innovative technologies will enhance diagnostic accuracy and contribute to better patient outcomes across various cancer types.

Table of Contents

Chapter 1 Methodology & Scope

  • 1.1 Market scope & definition
  • 1.2 Research design
    • 1.2.1 Research approach
    • 1.2.2 Data collection methods
  • 1.3 Base estimates & calculations
    • 1.3.1 Base year calculation
    • 1.3.2 Key trends for market estimation
  • 1.4 Forecast model
  • 1.5 Primary research and validation
    • 1.5.1 Primary sources
    • 1.5.2 Data mining sources

Chapter 2 Executive Summary

  • 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

  • 3.1 Industry ecosystem analysis
  • 3.2 Industry impact forces
    • 3.2.1 Growth drivers
      • 3.2.1.1 Rising cancer incidences
      • 3.2.1.2 Advancements in diagnostic technologies
      • 3.2.1.3 Growing awareness and demand
      • 3.2.1.4 Increased healthcare expenditures and investments
    • 3.2.2 Industry pitfalls & challenges
      • 3.2.2.1 High capital requirements
  • 3.3 Growth potential analysis
  • 3.4 Regulatory landscape
  • 3.5 Technological landscape
  • 3.6 Reimbursement scenario
  • 3.7 Future market trends
  • 3.8 Gap analysis
  • 3.9 Porter's analysis
  • 3.10 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

  • 4.1 Introduction
  • 4.2 Company market share analysis
  • 4.3 Company matrix analysis
  • 4.4 Competitive analysis of major market players
  • 4.5 Competitive positioning matrix
  • 4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Type, 2021 - 2032 ($ Mn)

  • 5.1 Key trends
  • 5.2 Genetic testing
    • 5.2.1 Next-generation sequencing (NGS)
    • 5.2.2 Fluorescence in situ hybridization (FISH)
    • 5.2.3 Polymerase chain reaction (PCR)
    • 5.2.4 In situ hybridization (ISH)
  • 5.3 Conventional testing

Chapter 6 Market Estimates and Forecast, By Application, 2021 - 2032 ($ Mn)

  • 6.1 Key trends
  • 6.2 Breast cancer
  • 6.3 Lung cancer
  • 6.4 Prostate cancer
  • 6.5 Colorectal cancer
  • 6.6 Melanoma
  • 6.7 Other applications

Chapter 7 Market Estimates and Forecast, By End Use, 2021 - 2032 ($ Mn)

  • 7.1 Key trends
  • 7.2 Hospitals
  • 7.3 Diagnostic laboratories
  • 7.4 Cancer research institutes
  • 7.5 Other end use

Chapter 8 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

  • 8.1 Key trends
  • 8.2 North America
    • 8.2.1 U.S.
    • 8.2.2 Canada
  • 8.3 Europe
    • 8.3.1 Germany
    • 8.3.2 UK
    • 8.3.3 France
    • 8.3.4 Spain
    • 8.3.5 Italy
    • 8.3.6 Netherlands
    • 8.3.7 Rest of Europe
  • 8.4 Asia Pacific
    • 8.4.1 China
    • 8.4.2 Japan
    • 8.4.3 India
    • 8.4.4 Australia
    • 8.4.5 South Korea
    • 8.4.6 Rest of Asia Pacific
  • 8.5 Latin America
    • 8.5.1 Brazil
    • 8.5.2 Mexico
    • 8.5.3 Argentina
    • 8.5.4 Rest of Latin America
  • 8.6 Middle East and Africa
    • 8.6.1 South Africa
    • 8.6.2 Saudi Arabia
    • 8.6.3 UAE
    • 8.6.4 Rest of Middle East and Africa

Chapter 9 Company Profiles

  • 9.1 Abbott
  • 9.2 Agilent Technologies, Inc.
  • 9.3 Caris Life Sciences
  • 9.4 F. Hoffmann-La Roche Ltd
  • 9.5 Foundation Medicine, Inc.
  • 9.6 Guardant Health
  • 9.7 Hologic, Inc.
  • 9.8 Illumina, Inc.
  • 9.9 MedGenome
  • 9.10 Myriad Genetics, Inc.
  • 9.11 NeoGenomics Laboratories
  • 9.12 QIAGEN
  • 9.13 Quest Diagnostics Incorporated
  • 9.14 SOPHiA GENETICS
  • 9.15 Thermo Fisher Scientific, Inc.